HomeCompareATLKY vs ABBV

ATLKY vs ABBV: Dividend Comparison 2026

ATLKY yields 1.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATLKY wins by $34.1K in total portfolio value· pulled ahead in Year 9
10 years
ATLKY
ATLKY
● Live price
1.34%
Share price
$17.61
Annual div
$0.24
5Y div CAGR
61.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136.5K
Annual income
$60,838.37
Full ATLKY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ATLKY vs ABBV

📍 ATLKY pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATLKYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATLKY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATLKY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATLKY
Annual income on $10K today (after 15% tax)
$113.50/yr
After 10yr DRIP, annual income (after tax)
$51,712.61/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ATLKY beats the other by $30,656.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATLKY + ABBV for your $10,000?

ATLKY: 50%ABBV: 50%
100% ABBV50/50100% ATLKY
Portfolio after 10yr
$119.4K
Annual income
$42,805.06/yr
Blended yield
35.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ATLKY
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Altman Z
7.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATLKY buys
0
ABBV buys
0
No recent congressional trades found for ATLKY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATLKYABBV
Forward yield1.34%3.06%
Annual dividend / share$0.24$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR61.2%40.6%
Portfolio after 10y$136.5K$102.3K
Annual income after 10y$60,838.37$24,771.77
Total dividends collected$109.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ATLKY vs ABBV ($10,000, DRIP)

YearATLKY PortfolioATLKY Income/yrABBV PortfolioABBV Income/yrGap
1$10,915$215.24$11,550$430.00$635.00ABBV
2$12,033$353.95$13,472$627.96$1.4KABBV
3$13,463$587.87$15,906$926.08$2.4KABBV
4$15,397$990.91$19,071$1,382.55$3.7KABBV
5$18,182$1,707.21$23,302$2,095.81$5.1KABBV
6$22,492$3,037.21$29,150$3,237.93$6.7KABBV
7$29,727$5,660.34$37,536$5,121.41$7.8KABBV
8$43,078$11,270.54$50,079$8,338.38$7.0KABBV
9← crossover$70,699$24,605.76$69,753$14,065.80+$946.00ATLKY
10$136,486$60,838.37$102,337$24,771.77+$34.1KATLKY

ATLKY vs ABBV: Complete Analysis 2026

ATLKYStock

Atlas Copco AB, together with its subsidiaries, provides productivity solutions. The company operates through Compressor Technique, Vacuum Technique, Industrial Technique, and Power Technique segments. It offers piston compressors, oil-free tooth and scroll compressors, rotary screw compressors, oil-free blowers, oil-free centrifugal compressors, gas and process compressors, air and gas treatment equipment, and medical air solutions primarily for use in the manufacturing and process industries. The company also provides oil-sealed rotary vane, dry, and liquid ring vacuum pumps; and turbomolecular and cryogenic pumps, as well as abatement and integrated systems for the semiconductor and scientific, chemical process, food packaging, and paper handling industries. In addition, it offers pneumatic, hydraulic, and electric assembly tools, as well as control systems and associated software for safety-critical tightening; self-pierce riveting tools, dispensing equipment for adhesives and sealants, and flow drill fastening equipment; material removal tools, drills, and other pneumatic products; and machine vision solutions for customers in the automotive and general industries. Further, the company provides portable compressors, boosters, generators, lighting towers, pumps, and construction and demolition tools for civil engineering, oil and gas, construction, manufacturing, exploration drilling, and demolition industries, as well as specialty rental services. It operates in North America, South America, Europe, Africa, the Middle East, Asia, and Oceania. The company was founded in 1873 and is headquartered in Nacka, Sweden.

Full ATLKY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ATLKY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATLKY vs SCHDATLKY vs JEPIATLKY vs OATLKY vs KOATLKY vs MAINATLKY vs JNJATLKY vs MRKATLKY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.